Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study

Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has been shown to increase bone mineral density (BMD) and reduce the risk of fracture in postmenopausal women with osteoporosis. Cessation of denosumab is associated with rises in bone remodelling, reductions in BMD and an in...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Aliya, Alrob, Hajar Abu, Said, Hosay, Iqbal, Salman, Hweija, Ismail, Hussain, Sharjil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Bone and Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090192/
http://dx.doi.org/10.1210/jendso/bvab048.489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090192/
http://dx.doi.org/10.1210/jendso/bvab048.489

Ejemplares similares